1. Home
  2. GCTS vs MAIA Comparison

GCTS vs MAIA Comparison

Compare GCTS & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GCT Semiconductor Holding Inc.

GCTS

GCT Semiconductor Holding Inc.

HOLD

Current Price

$3.38

Market Cap

93.5M

Sector

Finance

ML Signal

HOLD

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

HOLD

Current Price

$1.28

Market Cap

77.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GCTS
MAIA
Founded
1998
2018
Country
United States
United States
Employees
126
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
93.5M
77.1M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
GCTS
MAIA
Price
$3.38
$1.28
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$3.50
N/A
AVG Volume (30 Days)
7.5M
547.8K
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.33
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$1,052.30
N/A
Revenue Next Year
$140.29
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.90
$0.87
52 Week High
$3.57
$3.19

Technical Indicators

Market Signals
Indicator
GCTS
MAIA
Relative Strength Index (RSI) 81.08 47.43
Support Level $1.24 $1.24
Resistance Level N/A $1.46
Average True Range (ATR) 0.40 0.08
MACD 0.19 0.00
Stochastic Oscillator 89.78 33.19

Price Performance

Historical Comparison
GCTS
MAIA

About GCTS GCT Semiconductor Holding Inc.

GCT Semiconductor Holding Inc is a designer and supplier of 5G and 4G LTE semiconductor solutions. It enabled fast and reliable 4G LTE connectivity to numerous commercial devices such as CPEs, mobile hotspots, routers, M2M applications, and smartphones, etc. The system-on-chip solutions integrate radio frequency, baseband modem, and digital signal processing functions, therefore offering complete 4G and 5G platform solutions with small form factors, low power consumption, high performance, high reliability, and cost-effectiveness. Geographically, operates in South Korea and the United States, with maximum revenue from the USA.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

Share on Social Networks: